Meningioma is a relatively serious disease because it is one of the intracranial tumors. Meningioma accounts for approximately 30% of primary intracranial tumors and is the second most prevalent intracranial tumor after glioma. The severity of meningioma is related to the size, location, grading, and clinical presentation of meningioma. Meningiomas usually grow slowly, have a long course, usually 2-4 years, and have mild symptoms, and most meningiomas are benign, so they are not considered serious brain tumors. However, when the neurological function is not compensated, the disease will deteriorate rapidly, which can seriously affect the patient’s life. There are a few meningiomas that grow rapidly, have a short course, and are prone to recurrence and interstitial changes after surgery, especially in children, which are still serious. Moreover, some meningiomas may also produce malignant lesions, which can produce significant clinical symptoms and affect daily life. Especially for some malignant disease changes, it can sometimes cause death in a short period of time, with a 5-year recurrence rate of 80% and a 5-year survival rate of only 35%-61% for high-grade meningiomas. Therefore, timely treatment is essential to reduce clinical discomfort and prolong survival. In conclusion, meningioma is not serious when it is small or asymptomatic, but when it develops to a certain extent or becomes malignant, it will definitely have an impact on the body. Therefore, early detection and treatment are needed.